JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, announced today that it has raised $62.5 million in a Series C venture round.

A new book, The Heart of Leonardo, features all of Leonardo's drawings on the heart and its physiology, accompanied by translations of his accompanying notes.

Inspired by a genetic mutation that keeps low-density lipoprotein levels extremely low, three pharmaceutical companies are developing cholesterol drugs that mimic the trait. The New York Times described how drug makers are scurrying to get these potential blockbusters to market.

The Charles & Barbara Duboc Cardio Health & Wellness Center is ushering in a new era for preventive cardiac care at Saint Luke's Hospital..

The American Heart Association (AHA) has awarded world-renowned cardiologist Dr. Valentin Fuster, MD, PhD, Director of Mount Sinai Heart at The Mount Sinai Medical Center, its prominent American Heart Association/American Stroke Association Ron Haddock International Impact Award.

A promising bipartisan bill that increases vital access and reimbursement for obesity screening and counseling services has been introduced in Congress, thanks in part to the Academy of Nutrition and Dietetics.

Vascular surgeon Jeffrey H. Lawson, MD, PhD, implanted a bioengineered vein graft June 5 in a patient with end-stage kidney disease in a two-hour procedure at Duke University Hospital in Durham. The operation launches the U.S. trial of the human cell-based product that Lawson helped develop. If the bioengineered veins prove beneficial for hemodialysis patients, then they may try to develop a graft for heart bypass surgeries.

The New York Times set the stage for the upcoming FDA meeting that revisits GlaxoSmithKline’s diabetes drug, rosiglitazone (Avandia). The FDA said it is trying to “resolve uncertainty” about the drug, which has been limited based on concerns about heightened cardiovascular risk.